Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Toripalimab adjuvant therapy after cervical lymphadenectomy for residual or recurrent cervical nodal nasopharyngeal carcinoma
ChiCTR2300068574Phase 2Recruiting
- Sponsor
- Sun Yat-sen University Cancer Center
- Start
- Mar 2023
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of toripalimab in nasopharyngeal carcinoma (NPC) (2 arms), sponsored by Sun Yat-sen University Cancer Center. Primary endpoint: failure-free survival. Started Mar 2023; status: recruiting.
02
Drugs
toripalimab
03
Conditions
nasopharyngeal carcinoma (NPC)
Beyond the preview
Go deeper on ChiCTR2300068574.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300068574.